Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
new york blog main
new york top stories
2
×
abbvie
acorda therapeutics
ampyra
antisense oligonucleotide
apokyn
apomorphine
benzodiazepines
biogen
biotech
blackstone group
blackstone life sciences
boston
columbia university
dalfampridine
david goldstein
depression
duopa
epi4k
epilepsy
essential tremor
inbrija
investing
kiran reddy
major depressive disorder
marcio souza
mylan
new york
parkinson's disease
paul matteis
perimenopausal depression
praxis precision medicines
ptc therapeutics
What
new
2
×
stop
2
×
acorda
aims
approved
backed
cause
ceo
cope
disease
drug
drugs
epilepsy
episodes
fda
friday
genes
genetic
gets
help
late
links
looms
marcio
meant
medications
medicines
mutations
neuro
nod
parkinson’s
patients
praxis
precision
research
rival
souza
treatment
turn
working
Language
unset
Current search:
stop
×
new
×
" new york top stories "
×
@xconomy.com
3 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms